Possible roles of insulin signaling in osteoblasts

References

• Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med 1990;115:254–72
   Google Scholar
• Ituarte EA, Halstead LR, Iida-Klein A, et al. Glucose transport system in UMR-106-01 osteoblastic osteosarcoma cells: regulation by insulin. Calcif Tissue Int 1989;45:27–33
   Google Scholar
• Kream BE, Smith MD, Canalis E, Raisz LG. Characterization of the effect of insulin on collagen synthesis in fetal rat bone. Endocrinology 1985;116:296–302
   PubMed Web of Science ®Google Scholar
• Pramojanee SN, Phimphilai M, Kumphune S, et al. Decreased jaw bone density and osteoblastic insulin signaling in a model of obesity. J Dent Res 2013;92:560–65
   Google Scholar
• Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res 1989;4:853–62
   PubMed Web of Science ®Google Scholar
• Yang J, Zhang X, Wang W, Liu J. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. Cell Biochem Funct 2010;28:334–41
   PubMed Web of Science ®Google Scholar
• Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996;59:492–5
   PubMed Web of Science ®Google Scholar
• Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99–109
   PubMed Web of Science ®Google Scholar
• Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799–806
   PubMed Web of Science ®Google Scholar
• White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1–4
   PubMed Web of Science ®Google Scholar
• Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005;45:828–33
   PubMed Web of Science ®Google Scholar
• White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002;283:E413–22
   PubMed Web of Science ®Google Scholar
• Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 2001;15:2099–111
   PubMed Web of Science ®Google Scholar
• Akune T, Ogata N, Hoshi K, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 2002;159:147–56
   Google Scholar
• Lee YH, White MF. Insulin receptor substrate proteins and diabetes. Arch Pharm Res 2004;27:361–70
   PubMed Web of Science ®Google Scholar
• Ogata N, Chikazu D, Kubota N, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000;105:935–43
   PubMed Web of Science ®Google Scholar
• Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature reviews 2006;7:85–96
   Google Scholar
• Avruch J, Khokhlatchev A, Kyriakis JM, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001;56:127–55
   PubMedGoogle Scholar
• Lovicu FJ, McAvoy JW. FGF-induced lens cell proliferation and differentiation is dependent on MAPK (ERK1/2) signalling. Development 2001;128:5075–84
   PubMed Web of Science ®Google Scholar
• Werner H, Le Roith D. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997;8:71–92
   PubMed Web of Science ®Google Scholar
• Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999;274:1865–8
   PubMed Web of Science ®Google Scholar
• Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998;333:471–90
   PubMed Web of Science ®Google Scholar
• Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005;183:3–12
   PubMedGoogle Scholar
• Bertrand L, Horman S, Beauloye C, Vanoverschelde JL. Insulin signalling in the heart. Cardiovasc Res 2008;79:238–48
   PubMed Web of Science ®Google Scholar
• Zundel W, Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev 1998;12:1941–6
   PubMed Web of Science ®Google Scholar
• Grey A, Chen Q, Xu X, et al. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 2003;144:4886–93
   PubMed Web of Science ®Google Scholar
• Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010;142:296–308
   PubMed Web of Science ®Google Scholar
• Thomas DM, Udagawa N, Hards DK, et al. Insulin receptor expression in primary and cultured osteoclast-like cells. Bone 1998;23:181–6
   PubMed Web of Science ®Google Scholar
• Kawamura N, Kugimiya F, Oshima Y, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PloS One 2007;2:e1058
   PubMed Web of Science ®Google Scholar
• Wei J, Karsenty G. Bone as a site of insulin resistance in type 2 diabetes. BioMed Central Proceedings 2012. 74 p
   Google Scholar
• Rached MT, Kode A, Xu L, et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 2010;11:147–60
   Google Scholar
• Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 2010;142:309–19
   PubMed Web of Science ®Google Scholar
• Zhang M, Xuan S, Bouxsein ML, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005–12
   PubMed Web of Science ®Google Scholar
• Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559–69
   PubMed Web of Science ®Google Scholar
• Irwin R, Lin HV, Motyl KJ, McCabe LR. Normal bone density obtained in the absence of insulin receptor expression in bone. Endocrinology 2006;147:5760–7
   PubMedGoogle Scholar
• Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007;40:345–53
   PubMed Web of Science ®Google Scholar
• Ogawa N, Yamaguchi T, Yano S, et al. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007;39:871–5
   Google Scholar
• Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005;65:1013–5
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev 2002;1:769–83
   Google Scholar
• Fulzele K, DiGirolamo DJ, Liu Z, et al. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007;282:25649–58
   PubMed Web of Science ®Google Scholar
• Bu YH, He YL, Zhou HD, et al. Insulin receptor substrate 1 regulates the cellular differentiation and the matrix metallopeptidase expression of preosteoblastic cells. J Endocrinol 2010;206:271–7
   Google Scholar
• Shimoaka T, Kamekura S, Chikuda H, et al. Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem 2004;279:15314–22
   Google Scholar
• Hoshi K, Ogata N, Shimoaka T, et al. Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage. J Bone Miner Res 2004;19:214–23
   PubMed Web of Science ®Google Scholar
• Tamemoto H, Kadowaki T, Tobe K, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 1994;372:182–6
   PubMed Web of Science ®Google Scholar
• Xiao G, Jiang D, Thomas P, et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 2000;275:4453–9
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci 2009;122:716–26
   PubMed Web of Science ®Google Scholar
• Liu X, Bruxvoort KJ, Zylstra CR, et al. Lifelong accumulation of bone in mice lacking Pten in osteoblasts. Proc Natl Acad Sci USA 2007;104:2259–64
   PubMedGoogle Scholar
• Burguera B, Brunetto A, Garcia-Ocana A, et al. Leptin increases proliferation of human steosarcoma cells through activation of PI(3)-K and MAPK pathways. Med Sci Monit 2006;12:BR341–9
   Google Scholar
• Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes – a meta-analysis. Osteoporos Int 2007;18:427–44
   PubMed Web of Science ®Google Scholar
• Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355–65
   PubMed Web of Science ®Google Scholar
• Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diab Care 2008;31:S262–8
   PubMed Web of Science ®Google Scholar
• Karimifar M, Pasha MA, Salari A, et al. Evaluation of bone loss in diabetic postmenopausal women. J Res Med Sci 2012;17:1033–8
   Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005;48:1292–9
   PubMed Web of Science ®Google Scholar
• de L II, van der Klift M, de Laet CE, et al. Bone mineral density and fracture risk in type-2 diabetes mllitus: the Rotterdam Study. Osteoporos Int 2005;16:1713–20
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Kritz-Silverstein D. Does hyperinsulinemia preserve bone? Diabetes Care 1996;19:1388–92
   PubMed Web of Science ®Google Scholar
• Dennison EM, Syddall HE, Aihie Sayer A, et al. Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance? Diabetologia 2004;47:1963–8
   PubMed Web of Science ®Google Scholar
• Stolk RP, Van Daele PL, Pols HA, et al. Hyperinsulinemia and bone mineral density in an elderly population: The Rotterdam Study. Bone 1996;18:545–9
   PubMed Web of Science ®Google Scholar
• McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. J Cell Biochem 2007;102:1343–57
   PubMed Web of Science ®Google Scholar
• Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, et al. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000;11:455–9
   PubMed Web of Science ®Google Scholar
• Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004;19:1084–91
   PubMed Web of Science ®Google Scholar
• Yuksel O, Dokmetas HS, Topcu S, et al. Relationship between bone mineral density and insulin resistance in polycystic ovary syndrome. J Bone Miner Metab 2001;19:257–62
   PubMed Web of Science ®Google Scholar
• Reid IR. Relationships between fat and bone. Osteoporos Int 2008;19:595–606
   PubMed Web of Science ®Google Scholar
• Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456–69
   PubMed Web of Science ®Google Scholar
• Weinreb M, Shinar D, Rodan GA. Different pattern of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J Bone Miner Res 1990;5:831–42
   PubMed Web of Science ®Google Scholar
• Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 2011;26:677–80
   PubMedGoogle Scholar
• Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008;105:5266–70
   PubMed Web of Science ®Google Scholar
• Hwang YC, Jeong IK, Ahn KJ, Chung HY. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporos Int 2012;23:1337–42
   PubMed Web of Science ®Google Scholar
• Iki M, Tamaki J, Fujita Y, et al. Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int 2012;23:761–70
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:45–9
   PubMed Web of Science ®Google Scholar
• Kanazawa I, Yamaguchi T, Yamauchi M, et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2011;22:187–94
   PubMed Web of Science ®Google Scholar
• Ngarmukos C, Chailurkit LO, Chanprasertyothin S, et al. A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long-term follow-up cohort. Clin Endocrinol 2012;77:42–6
   PubMed Web of Science ®Google Scholar
• Saleem U, Mosley TH Jr, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010;30:1474–8
   PubMed Web of Science ®Google Scholar
• Yeap BB, Chubb SA, Flicker L, et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 2010;163:265–72
   PubMed Web of Science ®Google Scholar